Bioreactors Market (By Product Type: Single Use, Reusable; By Cell: Mammalian Cells, Bacterial Cells, Yeast Cells, Others; By Molecule: Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy, Others; By Usage: Developmental, Preclinical & Clinical, Commercial Production; By End-Use) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
The global bioreactors market size was evaluated at USD 9.3 billion in 2022 and it is expected to hold around USD 30.42 billion by 2032, growing at a CAGR of 12.58% between 2023 and 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Bioreactors are the vessels and the manufacturing devices which are used for the biological reactions of different organisms like bacteria and yeast are grown or even animal cells are grown when these are subjected to the proper environment. The growth of this cell is maintained due to the sustainable environment in the formation of a product.
The biotechnology industry and the pharmaceutical industry makes use of bioreactors to produce biological products, antibodies and even vaccines. To subject or to cultivate different organisms' industrial processes also make use of bioreactors which are used for treating chronic diseases. Many pharmaceutical products make use of bioreactors in controlled conditions.
Monoclonal antibiotics have a great demand in various nations across the globe, due to which the bioreactors market is expected to see significant growth during the forecast. As the amount of funds received through government organizations and private organizations have grown in recent times in order to develop different types of vaccines for various diseases, the market will show subsequent growth. Single-use bioreactors also have a good demand, and it will generate a large amount of revenue in the long run.
The Pharmaceutical industry and the biotechnology sector make maximum use of bioreactors. As both of these industries are developing and increasing, the bioreactors market is also expected to grow. Technological development is also expected to play an instrumental role in the use of advanced bioreactors and various equipment of advanced nature. Cultivation parameters can be monitored through the help of screens, and all of these advanced features will lead to the growth of the market. Quality data can be collected and gathered through the use of such developments, and it also leads to less human intervention.
Advanced bioreactors are receiving more funds, and the market players are also engaged in the manufacturing of these bioreactors. Constant research and development activities in the field of bioreactors will help in the growth of the market. Clinical trials and preclinical trials have increased. Research and development activities for microbial applications and cell culture have also grown in recent times. All of these factors will lead to the growth of the market during the forecast period.
As there has been an increase in different types of chronic diseases across the globe like diabetes, cancer and cardiovascular diseases, the need for various therapies associated with all of these diseases will lead to the growth of the bioreactors market. The introduction of novel therapies for treating cancer will also create more demand for bioreactors.
Report Coverage | Details |
Market Size in 2023 | USD 10.47 Billion |
Market Size by 2032 | USD 30.42 Billion |
Growth Rate from 2023 to 2032 | CAGR of 12.58% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Segments Covered | By Product Type, By Cell, By Molecule, By Usage and By End-Use |
Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Key Market Drivers
Development of preventive vaccines - In order to manufacture different types of vaccines that play a significant role in preventing various diseases will lead to the growth of the market. In recent times after the outbreak of the COVID-19 pandemic, the demand for COVID-19 vaccines had increased across the globe and the need for bioreactors of the clinical stage had also increased. Bioreactors were adopted on a large scale in various pharmaceutical industries for various procedures.
Organism cultivation - Bioreactors act as the apparatus for the cultivation of organisms like yeast, bacteria, animal cells and mammalian cells. All these are done in a controlled environment. Industrial processes also make use of bioreactors for the manufacturing of pharmaceutical products like monoclonal antibodies and vaccines. Biologicals are produced in a commercial way, and this also has a good application for bioreactors, due to which the adoption of this product will be more in the healthcare sector.
Technological advancements - In the coming years, market growth will be augmented by constant advancements in the features of the bioreactors and the processing of the bioreactors. Proactive involvement of the manufacturers of various nations in developing advanced technology which shall provide cost-effective bioreactors and help in the manufacturing of large-scale products, will lead to the growth of the market. There are many benefits associated with the use of advanced bioreactors, and all of these benefits will generate good revenue.
Processing large volumes of products and increasing the volume as much as possible with the use of advanced bioreactors. It enhances efficiency and it also simplifies the procedure. Single-use bioreactors have a greater adoption as this technology is better and provides good benefits for operations.
Key Market Challenges
Low-capacity bioreactors - Many different types of bioreactors are available in the market, and the single-use ones have less capacity in any process and procedure, and this happens to pose a challenge in the growth of the market.
The reusable bioreactors segment is expected to generate maximum revenue which is estimated to be about 76%, as most organizations prefer reusable bioreactors and the growth in the adoption of these bioreactors for bulk manufacturing of products in the healthcare industry will increase revenue size. These bioreactors have a higher volume of capacity and better scalability which will eventually accelerate the market expansion.
The demand for single-use bioreactors will be more very flexible, and easy and quick deployment is needed. Cross-contamination is prevented with the use of single-use bioreactors, and as these bioreactors enhance safety, the market demand for single-use bioreactors will also grow. Single-use bioreactors are less expensive as compared to traditional bioreactors, and the implementation cost of these bioreactors is less.
Depending on the cells, the bioreactors market can be segmented into yeast cells, Mammalian cells, bacterial cells and a few other cells. The segment of mammalian cells will generate maximum revenue. The demand for bioreactors will be more due to the increased use of these cells in the commercial production and development of various vaccines and proteins that are used in therapeutic procedures. Viral analogs are also generated with the help of these cells, which are extremely significant for regenerative medicines, and this will be instrumental in increasing the revenue size of the bioreactors market.
The vaccine segment will dominate the market and will grow significantly in the coming years. Recently, the demand for COVID vaccines has increased drastically, due to which significant growth has been registered. Various disorders of a chronic nature and rare disorders have significantly increased the demand for bioreactors. Research and development activities conducted for developing different vaccines will accelerate market growth. Activity associated with the development of vaccines will stimulate market expansion.
The need for bioreactors in clinical trials and preclinical trials for developing various drugs will increase significantly during the forecast period. Bioreactors are used in the clinical segments, preclinical segments,s and developmental segments. Growth opportunities will be provided due to a growing number of cases of chronic diseases.
Rare diseases have also increased in recent times, and the development of drugs for such diseases will create more demand for bioreactors. Bioreactors of smaller scale will also have good demand in the market in order to develop new drugs that could treat rare diseases.
The biopharma manufacturer segment will have a larger market share which is estimated to be about 43%. Advanced technologies are adopted on a large scale in order to simplify manufacturing procedures due to which the need for such products will grow. Forthcoming years will see a maximum application of bioreactors in manufacturing and developing complex molecules like proteins and nucleic acids. As the number of pharmaceutical industries and biotechnology industries are going, the demand for
bioreactors will grow significantly. In developing nations, the capacity for manufacturing biopharmaceutical products is also increasing. The healthcare industry is expected to adopt more and more bioreactors and innovative products for various procedures. Intensive procedures adopted in modern times require the higher transfer of oxygen and efficient removal of carbon dioxide due to which the advanced by the actors will have a greater demand during the forecast period.
Significant growth rate to be registered in the North American region for the bioreactors industry. Prominent manufacturers are present in the North American region due to which the market growth will be substantial. The number of patients suffering with chronic diseases have also grown in recent times and the geriatric population is also increasing, due to which the demand for bioreactors will be more in the North American region.
The amount of expenditure made on research and development activities is also increasing in the North American region, and this will drive market growth in the forecast period. The facilities provided for conducting research and development activities are also favourable and it will show a significant increase. Such activities are supported by government investments as the demand for various vaccines has increased.
The development of the same after the outbreak of the COVID-19 pandemic has also grown. Good opportunities for the growth of the market will be provided by the North American region in the coming years.
Segments Covered in the Report
(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)
By Product Type
By Cell
By Molecule
By Usage
By End-Use
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Bioreactors Market
5.1. COVID-19 Landscape: Bioreactors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Bioreactors Market, By Product Type
8.1. Bioreactors Market, by Product Type, 2023-2032
8.1.1. Single-Use
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Reusable
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Bioreactors Market, By Cell
9.1. Bioreactors Market, by Cell, 2023-2032
9.1.1. Mammalian Cells
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Bacterial Cells
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Yeast Cells
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Bioreactors Market, By Molecule
10.1. Bioreactors Market, by Molecule, 2023-2032
10.1.1. Monoclonal Antibodies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Vaccines
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Recombinant Proteins
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Stem Cells
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Gene Therapy
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Bioreactors Market, By Usage
11.1. Bioreactors Market, by Usage, 2023-2032
11.1.1. Developmental, Preclinical & Clinical
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Commercial Production
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Bioreactors Market, By End-Use
12.1. Bioreactors Market, by End-Use, 2023-2032
12.1.1. Research and Development (R&D) Organizations
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Biopharmaceutical (biopharma) Manufacturers
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Contract Manufacturing Organizations (CMOS)
12.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Bioreactors Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.1.2. Market Revenue and Forecast, by Cell (2020-2032)
13.1.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.1.4. Market Revenue and Forecast, by Usage (2020-2032)
13.1.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Cell (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Usage (2020-2032)
13.1.6.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Cell (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.1.7.4. Market Revenue and Forecast, by Usage (2020-2032)
13.1.7.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.2.2. Market Revenue and Forecast, by Cell (2020-2032)
13.2.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.2.4. Market Revenue and Forecast, by Usage (2020-2032)
13.2.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Cell (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.2.7. Market Revenue and Forecast, by Usage (2020-2032)
13.2.8. Market Revenue and Forecast, by End-Use (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Cell (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.2.10. Market Revenue and Forecast, by Usage (2020-2032)
13.2.11. Market Revenue and Forecast, by End-Use (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Cell (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Usage (2020-2032)
13.2.13. Market Revenue and Forecast, by End-Use (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Cell (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Usage (2020-2032)
13.2.15. Market Revenue and Forecast, by End-Use (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.3.2. Market Revenue and Forecast, by Cell (2020-2032)
13.3.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.3.4. Market Revenue and Forecast, by Usage (2020-2032)
13.3.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Cell (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Usage (2020-2032)
13.3.7. Market Revenue and Forecast, by End-Use (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Cell (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Usage (2020-2032)
13.3.9. Market Revenue and Forecast, by End-Use (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Cell (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Usage (2020-2032)
13.3.10.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Cell (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Usage (2020-2032)
13.3.11.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.4.2. Market Revenue and Forecast, by Cell (2020-2032)
13.4.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.4.4. Market Revenue and Forecast, by Usage (2020-2032)
13.4.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Cell (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Usage (2020-2032)
13.4.7. Market Revenue and Forecast, by End-Use (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Cell (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Usage (2020-2032)
13.4.9. Market Revenue and Forecast, by End-Use (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Cell (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Usage (2020-2032)
13.4.10.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Cell (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Usage (2020-2032)
13.4.11.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.5.2. Market Revenue and Forecast, by Cell (2020-2032)
13.5.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.5.4. Market Revenue and Forecast, by Usage (2020-2032)
13.5.5. Market Revenue and Forecast, by End-Use (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Cell (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Usage (2020-2032)
13.5.7. Market Revenue and Forecast, by End-Use (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Cell (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Molecule (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Usage (2020-2032)
13.5.8.5. Market Revenue and Forecast, by End-Use (2020-2032)
Chapter 14. Company Profiles
14.1. GE Healthcare
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Merck KGaA
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Eppendorf AG
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Sartorius AG
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Thermo Fisher Scientific Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. BBI-Biotech GmbH
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Bioengineering AG
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Danaher Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Getinge
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Infos HT
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client